Sun’s Ilumya Set For Phase III In Psoriatic Arthritis After ‘Promising’ Results
Executive Summary
Sun releases what it says are promising interim data from a Phase II study on Ilumya, its flagship first novel biologic, in the additional indication of psoriatic arthritis, where the antibody met the primary endpoint in its first trial in this setting.
You may also be interested in...
Sun Wants To Join The Biosimilars Party, In Time
India's Sun Pharma is to foray into biosimilars, targeting first approval status for “third wave” products. It trails several peers and the changed stance comes as biosimilars gain traction in markets including the US, where experts have predicted a “coming out party” in the next few years.
Sun Wants To Join The Biosimilars Party, In Time
India's Sun Pharma is to foray into biosimilars, targeting first approval status for “third wave” products. It trails several peers and the changed stance comes as biosimilars gain traction in markets including the US, where experts have predicted a “coming out party” in the next few years.
Sun Sees New Prescriptions Drought Amid COVID-19
Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.